Aldeyra Therapeutics
ALDX
87 hedge funds and large institutions have $174M invested in Aldeyra Therapeutics in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 21 closing their positions.
192% more call options, than puts
Call options by funds: $919K | Put options by funds: $315K
185% more capital invested
Capital invested by funds: $61.1M → $174M (+$113M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
12.46% more ownership
Funds ownership: 49.17% → 61.63% (+12%)
4% more funds holding
Funds holding: 84 → 87 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$20.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.3M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.89M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$3.41M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.92M |
| 3 |
Millennium Management
New York
|
-$1.51M |
| 4 |
Morgan Stanley
New York
|
-$1.37M |
| 5 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.31M |
ALDX Hedge Fund Activity: Q3 2020 in Review
87 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2020, worth a combined $174M — up 185% from $61.1M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ALDX positions and 21 closed out — a net gain of 3 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $20.7M. The largest seller was Prosight Management, cutting an estimated $3.41M.
- 87 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2020, up from 84 in Q2 2020.
- Funds reported $174M of Aldeyra Therapeutics stock for Q3 2020, up 185% quarter-over-quarter.
- 24 funds opened new Aldeyra Therapeutics positions in Q3 2020 and 21 closed out, a net change of +3 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2020 was Perceptive Advisors, an estimated $20.7M added.
- The largest Aldeyra Therapeutics seller in Q3 2020 was Prosight Management, an estimated $3.41M sold.
Based on aggregated 13F filings for Q3 2020.